Nirogacestat for Ovarian Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial studies nirogacestat, a drug that blocks a protein to slow down tumor growth, in adult patients with ovarian granulosa cell tumors that have come back or did not respond to previous treatments. Nirogacestat is being tested in combination with other agents for certain types of cancer.
Will I have to stop taking my current medications?
The trial requires that you stop taking certain treatments for ovarian granulosa cell tumors, such as hormonal therapy, chemotherapy, immunotherapy, targeted therapy, or any investigational treatment, at least 28 days before starting the study treatment.
Are You a Good Fit for This Trial?
This trial is for adults with recurrent ovarian granulosa cell tumors who've had at least one systemic therapy and can't have surgery or radiation. They must have measurable tumor growth, no major heart events or abnormal QT intervals recently, and not be on certain treatments like monoclonal antibodies within the last 28 days.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive open-label nirogacestat until disease progression or unacceptable toxicity
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Nirogacestat
Find a Clinic Near You
Who Is Running the Clinical Trial?
SpringWorks Therapeutics, Inc.
Lead Sponsor